Role of B cell-activating factor in chronic obstructive pulmonary disease

American Journal of Respiratory and Critical Care Medicine

Volumn 192, Issue 6, 2015, Pages 706-718

  Seys, Leen J M ^a   Verhamme, Fien M ^a   Schinwald, Anja ^b   Hammad, Hamida ^a,c   Cunoosamy, Danen Mootoosamy ^b   Bantsimba Malanda, Claudie ^d   Sabirsh, Alan ^b   McCall, Eileen ^b   Flavell, Liz ^e   Herbst, Ronald ^d   Provoost, Sharen ^a   Lambrecht, Bart N ^a,c   Joos, Guy F ^a   Brusselle, Guy G ^a   Bracke, Ken R ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b ASTRAZENECA R AND D   (Sweden)

^c GHENT UNIVERSITY   (Belgium)

^d MEDIMMUNE   (United States)

^e ASTRAZENECA   (United Kingdom)

Author keywords

B cell activating factor; B lymphocytes; COPD; Lymphoid follicles

Indexed keywords

B CELL ACTIVATING FACTOR; B CELL ACTIVATING FACTOR RECEPTOR; B CELL ACTIVATING FACTOR RECEPTOR FC; B CELL MATURATION ANTIGEN; CD163 ANTIGEN; CD19 ANTIGEN; CD69 ANTIGEN; CHEMOKINE RECEPTOR CXCR5; CIGARETTE SMOKE; CXCL9 CHEMOKINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HYBRID PROTEIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN M; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 4; INTERLEUKIN 6; KERATINOCYTE DERIVED CHEMOKINE; MONOCYTE CHEMOTACTIC PROTEIN 1; PHOSPHATE BUFFERED SALINE; RANTES; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; SMOKE; TNFSF13B PROTEIN, HUMAN;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B LYMPHOCYTE; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DENDRITIC CELL; DOWN REGULATION; EMPHYSEMA; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBROBLASTIC RETICULAR CELL; FOLLICULAR DENDRITIC CELL; GENE EXPRESSION; GENE LOCATION; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOHISTOCHEMISTRY; LUNG ALVEOLUS MACROPHAGE; LUNG LAVAGE; LYMPH FOLLICLE; MAJOR CLINICAL STUDY; MALE; MOUSE; NEUTROPHIL; NONHUMAN; POLARIZATION; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; RESPIRATORY EPITHELIUM; RETICULUM CELL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SMOOTH MUSCLE FIBER; UPREGULATION; ADAPTIVE IMMUNITY; ADVERSE EFFECTS; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; IMMUNOLOGY; LUNG; LYMPHOID TISSUE; MACROPHAGE; METABOLISM; MIDDLE AGED; SMOKE; SMOKING;

ADAPTIVE IMMUNITY; AGED; ANIMALS; B-CELL ACTIVATING FACTOR; B-LYMPHOCYTES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG; LYMPHOID TISSUE; MACROPHAGES; MALE; MICE; MICE, INBRED C57BL; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SMOKE; SMOKING;

EID: 84942241939     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201501-0103OC     Document Type: Article

References (44)

1. Brusselle GG, Joos GF, Bracke KR. New insights into the immunology of chronic obstructive pulmonary disease. Lancet 2011;378:1015-1026.
2. Zhu X, Gadgil AS, Givelber R, George MP, Stoner MW, Sciurba FC, Duncan SR. Peripheral T cell functions correlate with the severity of chronic obstructive pulmonary disease. J Immunol 2009;182:3270-3277.
3. Saetta M, Di Stefano A, Turato G, Facchini FM, Corbino L, Mapp CE, Maestrelli P, Ciaccia A, Fabbri LM. CD81 T-lymphocytes in peripheral airways of smokers with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998;157:822-826.
4. Cosio MG, Saetta M, Agusti A. Immunologic aspects of chronic obstructive pulmonary disease. N Engl J Med 2009;360:2445-2454.
5. Gosman MM, Willemse BW, Jansen DF, Lapperre TS, van Schadewijk A, Hiemstra PS, Postma DS, Timens W, Kerstjens HA; Groningen and Leiden Universities Corticosteroids in Obstructive Lung Disease Study Group. Increased number of B-cells in bronchial biopsies in COPD. Eur Respir J 2006;27:60-64.
6. Hogg JC, Chu F, Utokaparch S, Woods R, Elliott WM, Buzatu L, Cherniack RM, Rogers RM, Sciurba FC, Coxson HO, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 2004;350:2645-2653.
7. van der Strate BW, Postma DS, Brandsma CA, Melgert BN, Luinge MA, Geerlings M, Hylkema MN, van den Berg A, Timens W, Kerstjens HA. Cigarette smoke-induced emphysema: a role for the B cell? Am J Respir Crit Care Med 2006;173:751-758.
8. Sapey E, Wood AM. Auto-antibodies and inflammation: a case of the chicken and the egg? Am J Respir Crit Care Med 2011;183:959-960.
9. Rinaldi M, Lehouck A, Heulens N, Lavend'homme R, Carlier V, Saint-Remy JM, Decramer M, Gayan-Ramirez G, Janssens W. Antielastin B-cell and T-cell immunity in patients with chronic obstructive pulmonary disease. Thorax 2012;67:694-700.
10. Nuñez B, Sauleda J, AntóJM, Julià MR, Orozco M, MonsóE, Noguera A, Gómez FP, Garcia-Aymerich J, Agustí A; PAC-COPD Investigators. Anti-tissue antibodies are related to lung function in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2011;183:1025-1031.
11. Lee SH, Goswami S, Grudo A, Song LZ, Bandi V, Goodnight-White S, Green L, Hacken-Bitar J, Huh J, Bakaeen F, et al. Antielastin autoimmunity in tobacco smoking-induced emphysema. Nat Med 2007;13:567-569.
12. Brusselle GG, Demoor T, Bracke KR, Brandsma CA, Timens W. Lymphoid follicles in (very) severe COPD: beneficial or harmful? Eur Respir J 2009;34:219-230.
13. Mackay F, Browning JL. BAFF: a fundamental survival factor for B cells. Nat Rev Immunol 2002;2:465-475.
14. Mackay F, Schneider P. Cracking the BAFF code. Nat Rev Immunol 2009;9:491-502.
15. Polverino F, Baraldo S, Bazzan E, Agostini S, Turato G, Lunardi F, Balestro E, Damin M, Papi A, Maestrelli P, et al. A novel insight into adaptive immunity in chronic obstructive pulmonary disease: B cell activating factor belonging to the tumor necrosis factor family. Am J Respir Crit Care Med 2010;182:1011-1019.
16. Seys LJM, Verhamme FM, Cunoosamy DM, Herbst R, Lambrecht BN, Joos GF, Brusselle GG, Bracke KR. Role of B-cell activating factor (BAFF) in cigarette-smoke induced lymphoid follicle formation and chronic obstructive pulmonary disease (COPD) [abstract]. Am J Respir Crit Care Med 2014;189:A3915.
17. D'hulst AI, Vermaelen KY, Brusselle GG, Joos GF, Pauwels RA. Time course of cigarette smoke-induced pulmonary inflammation in mice. Eur Respir J 2005;26:204-213.
18. Van Pottelberge GR, Bracke KR, Demedts IK, De Rijck K, Reinartz SM, van Drunen CM, Verleden GM, Vermassen FE, Joos GF, Brusselle GG. Selective accumulation of langerhans-type dendritic cells in small airways of patients with COPD. Respir Res 2010;11:35.
19. Bracke KR, D'hulst AI, Maes T, Moerloose KB, Demedts IK, Lebecque S, Joos GF, Brusselle GG. Cigarette smoke-induced pulmonary inflammation and emphysema are attenuated in CCR6-deficient mice. J Immunol 2006;177:4350-4359.
20. Demoor T, Bracke KR, Maes T, Vandooren B, Elewaut D, Pilette C, Joos GF, Brusselle GG. Role of lymphotoxin-alpha in cigarette smoke-induced inflammation and lymphoid neogenesis. Eur Respir J 2009;34:405-416.
21. Vermaelen KY, Carro-Muino I, Lambrecht BN, Pauwels RA. Specific migratory dendritic cells rapidly transport antigen from the airways to the thoracic lymph nodes. J Exp Med 2001;193:51-60.
22. Vermaelen K, Pauwels R. Accurate and simple discrimination of mouse pulmonary dendritic cell and macrophage populations by flow cytometry: methodology and new insights. Cytometry A 2004;61:170-177.
23. D'hulst AI, Maes T, Bracke KR, Demedts IK, Tournoy KG, Joos GF, Brusselle GG. Cigarette smoke-induced pulmonary emphysema in scid-mice. Is the acquired immune system required? Respir Res 2005;6:147.
24. Thurlbeck WM. Measurement of pulmonary emphysema. Am Rev Respir Dis 1967;95:752-764.
25. Saetta M, Shiner RJ, Angus GE, Kim WD, Wang NS, King M, Ghezzo H, Cosio MG. Destructive index: a measurement of lung parenchymal destruction in smokers. Am Rev Respir Dis 1985;131:764-769.
26. Bracke KR, Verhamme FM, Seys LJ, Bantsimba-Malanda C, Cunoosamy DM, Herbst R, Hammad H, Lambrecht BN, Joos GF, Brusselle GG. Role of CXCL13 in cigarette smoke-induced lymphoid follicle formation and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2013;188:343-355.
27. Vincent FB, Saulep-Easton D, Figgett WA, Fairfax KA, Mackay F. The BAFF/APRIL system: emerging functions beyond B cell biology and autoimmunity. Cytokine Growth Factor Rev 2013;24:203-215.
28. Vincent FB, Morand EF, Schneider P, Mackay F. The BAFF/APRIL system in SLE pathogenesis. Nat Rev Rheumatol 2014;10:365-373.
29. Scholz JL, Crowley JE, Tomayko MM, Steinel N, O'Neill PJ, Quinn WJ III, Goenka R, Miller JP, Cho YH, Long V, et al. BLyS inhibition eliminates primary B cells but leaves natural and acquired humoral immunity intact. Proc Natl Acad Sci USA 2008;105:15517-15522.
30. Sindhava VJ, Scholz JL, Cancro MP. Roles for BLyS family members in meeting the distinct homeostatic demands of innate and adaptive B cells. Front Immunol 2013;4:37.
31. Navarra SV, Guzmán RM, Gallacher AE, Hall S, Levy RA, Jimenez RE, Li EK, Thomas M, Kim HY, León MG, et al.; BLISS-52 Study Group. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 2011;377:721-731.
32. Furie R, Petri M, Zamani O, Cervera R, Wallace DJ, TegzováD, Sanchez-Guerrero J, Schwarting A, Merrill JT, Chatham WW, et al.; BLISS-76 Study Group. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 2011;63:3918-3930.
33. Chang SK, Arendt BK, Darce JR, Wu X, Jelinek DF. A role for BLyS in the activation of innate immune cells. Blood 2006;108:2687-2694.
34. Sutherland AP, Ng LG, Fletcher CA, Shum B, Newton RA, Grey ST, Rolph MS, Mackay F, Mackay CR. BAFF augments certain Th1-associated inflammatory responses. J Immunol 2005;174: 5537-5544.
35. Moisini I, Davidson A. BAFF: a local and systemic target in autoimmune diseases. Clin Exp Immunol 2009;158:155-163.
36. Hiemstra PS. Altered macrophage function in chronic obstructive pulmonary disease. Ann Am Thorac Soc 2013;10:S180-S185.
37. Frankenberger M, Menzel M, Betz R, Kassner G, Weber N, Kohlhäufl M, Häussinger K, Ziegler-Heitbrock L. Characterization of a population of small macrophages in induced sputum of patients with chronic obstructive pulmonary disease and healthy volunteers. Clin Exp Immunol 2004;138:507-516.
38. Kunz LI, Lapperre TS, Snoeck-Stroband JB, Budulac SE, Timens W, van Wijngaarden S, Schrumpf JA, Rabe KF, Postma DS, Sterk PJ, et al.; Groningen Leiden Universities Corticosteroids in Obstructive Lung Disease Study Group. Smoking status and anti-inflammatory macrophages in bronchoalveolar lavage and induced sputum in COPD. Respir Res 2011;12:34.
39. Shaykhiev R, Krause A, Salit J, Strulovici-Barel Y, Harvey BG, O'Connor TP, Crystal RG. Smoking-dependent reprogramming of alveolar macrophage polarization: implication for pathogenesis of chronic obstructive pulmonary disease. J Immunol 2009;183: 2867-2883.
40. Davies LC, Jenkins SJ, Allen JE, Taylor PR. Tissue-resident macrophages. Nat Immunol 2013;14:986-995.
41. Walters S, Webster KE, Sutherland A, Gardam S, Groom J, Liuwantara D, Mariño E, Thaxton J, Weinberg A, Mackay F, et al. Increased CD41Foxp31 T cells in BAFF-transgenic mice suppress T cell effector responses. J Immunol 2009;182:793-801.
42. Chen M, Lin X, Liu Y, Li Q, Deng Y, Liu Z, Brand D, Guo Z, He X, Ryffel B, et al. The function of BAFF on T helper cells in autoimmunity. Cytokine Growth Factor Rev 2014;25:301-305.
43. John-Schuster G, Hager K, Conlon TM, Irmler M, Beckers J, Eickelberg O, Yildirim AO. Cigarette smoke-induced iBALT mediates macrophage activation in a B cell-dependent manner in COPD. Am J Physiol Lung Cell Mol Physiol 2014;307:L692-L706.
44. Polverino F, Cosio BG, Pons J, Laucho-Contreras M, Tejera P, Iglesias A, Rios A, Jahn A, Sauleda J, Divo M, et al. B cell-activating factor: an orchestrator of lymphoid follicles in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2015;192:695-705.